| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	With several patients already enrolled in the study, PRISM PMR is designed to evaluate the Swoop® system's clinical utility...
 
																	
 
																	
 
																	
 
																	 
																	
 
																	
 
																	
 
																	Hyperfine (NASDAQ:HYPR) sees Q3 sales of $3.400 million vs $3.507 million analyst estimate.